Rotavirus vaccines

References

• Snyder JD, Merson MH. The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. Bull WHO 1982; 60: 605–13
   PubMed Web of Science ®Google Scholar
• Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RT. Gloval illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9: 565–72
   PubMed Web of Science ®Google Scholar
• The Pediatric ROTavisut European CommitTee (PROTECT). The paediatric burden of rotavirus disease in Europe. Epidemiol Infect 2006;134:908–16.
   Google Scholar
• Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006; 25: S7–11
   PubMed Web of Science ®Google Scholar
• Vesikari T, Isolauri E, D'Hondt E, Delem A, André FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984; 1: 977–81
   PubMed Web of Science ®Google Scholar
• Vesikari T, Isolauri E, Delem A, D'Hondt E, André FE, Beards GM, et al. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr 1985; 107: 189–94
   PubMed Web of Science ®Google Scholar
• Vesikari T, Ruuska T, Delem A, André FE, Beards GM, Flewett TH. Efficacy of 2 doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Paediatr Scand 1991; 80: 173–80
   PubMed Web of Science ®Google Scholar
• Ruuska T, Vesikari T, Delem A, André FE, Beards GM, Flewett TH. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scand J Infect Dis 1990; 22: 269–78
   PubMed Web of Science ®Google Scholar
• Vesikari T, Ruuska T, Bogaerts H, Delem A, André F. Dose-response study of RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants. Pediatr Infect Dis 1985; 4: 622–5
   PubMedGoogle Scholar
• Hanlon P, Hanlon L, Marsh V, Byass P, Shenton F, Hassan-King M, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987; 1: 1342–5
   PubMed Web of Science ®Google Scholar
• Lanata CF, Black RE, del Aguila R, Gil A, Verastegui H, Gerna G, et al. Protection of Peruvian children against rotavirus diarrhoea of specific serotypes by 1, 2, or 3 doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989; 159: 425–9
   Web of Science ®Google Scholar
• Linhares AC, Lanata CF, Hausdorff WP, Gabbay YB, Black RE. Reappraisal of the Peruvian and Brazilian lower titre tetravalent rhesus-human reassortant rotavirus vaccine efficacy trials: analysis by severity of diarrhoea. Pediatr Infect Dis J 1999; 18: 1001–6
   PubMed Web of Science ®Google Scholar
• Vesikari T, Kapikian AZ, Delem A, Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 1986; 153: 832–9
   PubMed Web of Science ®Google Scholar
• Vesikari T, Rautanen T, Varis T, Beards GM, Kapikian AZ. Rhesus rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. Am J Dis Child 1990; 144: 285–9
   PubMedGoogle Scholar
• Joensuu J, Koskenniemi E, Pang X-L, Vesikari T. Randomized placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350: 1205–9
   PubMed Web of Science ®Google Scholar
• Pérez-Schael I, Guntiñas MJ, Pérez M, Pagone V, Rojas AM, González R, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337: 1181–7
   PubMed Web of Science ®Google Scholar
• Ward RL, Bernstein EI. Lack of correlation between serum rotavirus antibody titres and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group. Vaccine 1995; 13: 1226–32
   PubMed Web of Science ®Google Scholar
• Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006; 24: 4821–9
   PubMed Web of Science ®Google Scholar
• Ward RL, Bernstein DI, Smith VE, Sander DS, Shaw A, Eiden JJ, et al. Rotavirus immunoglobulin A responses stimulated by each 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. J Infect Dis 2004; 189: 2290–3
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, for the US Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995;273:1191–6.
   PubMed Web of Science ®Google Scholar
• CDC. Intussusception among recipients of rotavirus vaccine – United States, 1998–1999. MMRV 1999;48:577–81.
   Google Scholar
• Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005; 192(Suppl 1)S36–43
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, et al. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis 2006; 194: 370–6
   PubMed Web of Science ®Google Scholar
• Bernstein D, Smith V, Sander D, Pax K, Schiff G, Ward R. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 1990; 162: 10055–62
   Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354: 23–33
   PubMed Web of Science ®Google Scholar
• Vesikari T, Itzler R, Matson DO, Santosham M, Christie CDC, Coia M, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across 3 regions (11 countries). Int J Infect Dis 2007; 11(Suppl 2)S29–35
   PubMed Web of Science ®Google Scholar
• Prevention of rotavirus gastroenteritis in infants and children. Recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR 2006;55:1–13.
   Google Scholar
• American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of Rotavirus Disease: Guidelines for Use of Rotavirus Vaccine. Pediatrics 2007;119:171–81.
   Google Scholar
• Bernstein DI, Smith VE, Sherwood JR, Schiff GM, Sander DS, DeFeudis D, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998; 16: 381–7
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomized placebo-controlled trial. Lancet 1999; 354: 287–90
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004; 22: 2836–42
   PubMed Web of Science ®Google Scholar
• Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24: 807–16
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354: 11–22
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 y of life in European infants: randomized, double-blind controlled study. Lancet 2007; 370: 1757–63
   PubMed Web of Science ®Google Scholar
• Vesikari T, van Damme P, Giaquinto C, Gray J, Mrukowicz J, Dagan R, , et al ESPID/ESPGHAN evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol (Suppl), in press.
   Google Scholar